Closed production cassette with pink culture medium inside the CUTISS automated manufacturing system, built with Tecan

Personal skin grafts, grown from a stamp-sized biopsy

denovoSkin™ is a two-layer skin graft made from the patient’s own cells, for people who need skin surgery after severe burns. It is grown in a closed, automated system and is now in Phase III, not yet approved.

Scientist in full cleanroom gear holding up a sheet of denovoSkin with two forceps
From a small biopsy to a graft many times larger, made from the patient’s own skin cells.
  1. Biopsy
  2. Isolate
  3. Expand
  4. Tissue formation
  5. Ready for grafting

From a stamp-sized biopsy to a sheet of skin

Automation layer: a patented, fully closed, end-to-end production system, industrialised together with Tecan.

A stamp-sized biopsy

A small biopsy of healthy skin is harvested from the patient. Everything that follows starts from the patient’s own cells.

A thin, translucent sheet of denovoSkin lifted with two pairs of forceps above a culture dish

Two layers, grown from the patient’s own skin

denovoSkin™ is an advanced therapy medicinal product, bioengineered in scalable quantities from a small biopsy of a patient’s healthy skin. CUTISS is developing it to replace autografting, today’s standard of care, which is limited by donor site shortage.

EpidermisThe top, protective layer.
DermisThe structural layer below.

Orphan Drug Designation for the treatment of burns from Swissmedic, EMA and the FDA. denovoSkin™ is investigational and not yet approved.

“The key point is that it is a personalized bilayer graft.”Daniela Marino, co-founder and CEO, in UZH News, January 2026

Where would you like to start?

Surgeons and burn centres

A randomised, controlled Phase III trial in severe burns is ongoing in burn centres across the EU and Switzerland, after Phase I and three Phase II studies.

See clinical development

Investors and partners

Series C of CHF 56 million in 2025, a manufacturing partnership with Tecan, and selection for EIC Accelerator support in November 2026.

Investor news

Patients and families

What denovoSkin™ is, how it is being studied and what it means that it is not yet approved, in plain language.

Information for patients
Closed production cassette with pink culture medium inside CUTISS automated manufacturing equipment

Personalised tissue, produced like a platform

CUTISS manufactures denovoSkin™ in its certified GMP facility near Zurich and has built a first-in-class automation platform for scalable, decentralised production of personalised tissue.

  • April 2025 · Partnership with Tecan to industrialise the automated platform
  • May 2026 · U.S. patent for automated skin graft production methods
  • November 2026 · EIC Accelerator selection for denovoProd, automated denovoSkin™ production
How production scales